Late lines of treatment benefit survival in metastatic breast cancer in current practice?
Abstract Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the “taxane...
Gespeichert in:
| Veröffentlicht in: | Breast (Edinburgh) 2011-12, Vol.20 (6), p.574-578 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 6 |
| container_start_page | 574 |
| container_title | Breast (Edinburgh) |
| container_volume | 20 |
| creator | Planchat, E Abrial, C Thivat, E Mouret-Reynier, M.A Kwiatkowski, F Pomel, C Wang-Lopez, Q Chollet, P Nabholtz, J.M Durando, X |
| description | Abstract Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the “taxane/anti-aromatase era” for each line given. 529 received CT and 383 hormonotherapy. OS was assessed; from the date of first metastasis and from Day 1 of each CT line. Median OS was 34.1 months; 226 patients received >3 lines of CT with a steady median OS for late lines, 11.4 months per line (range 10.4–12.6). Clinical benefit after the third line of CT was obtained for 29.2–36.6% of patients. CT lasted 11.7 months “on” versus 20.6 months “off” CT. These results may support the use of more than 3 CT lines; each line can contribute to a longer survival. |
| doi_str_mv | 10.1016/j.breast.2011.07.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905963777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0960977611001603</els_id><sourcerecordid>905963777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-4c1b286ba6eb38a31017a22f4935d871e0a2fbbb1b56dde483cc4456f4a050633</originalsourceid><addsrcrecordid>eNqFkT1v1TAUhi1URG8L_wAhb0wJx3ZiJ0urqgKKdCUG6NDJsp0TyZd8XGznSv33dZTSgaWTB78fOs9LyEcGJQMmvxxKG9DEVHJgrARVAoM3ZMdqwQsBDZyRHbQSilYpeU4uYjwAQCtk846cc9bUnAm5Iw97k5AOfsJI556mHJlGnBK1OGHvE41LOPmTGaif6IgpF5rkHd26qTOTw7D-uSWE1XcMxmUBXr8nb3szRPzw_F6S-29ff9_eFfuf33_c3uwLV0meisoxyxtpjUQrGiPybcpw3letqLtGMQTDe2sts7XsOqwa4VxV1bKvDNQghbgkn7fcY5j_LhiTHn10OAxmwnmJuoW6lUIplZXVpnRhjjFgr4_BjyY8agZ6ZaoPertLr0w1KJ2ZZtun54LFjti9mP5BzIKrTYD5zJPHoKPzmMF0PqBLupv9aw3_B7i8iHdm-IOPGA_zEqaMUDMduQb9a911nZUxyJkgxBN5yZ8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905963777</pqid></control><display><type>article</type><title>Late lines of treatment benefit survival in metastatic breast cancer in current practice?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Planchat, E ; Abrial, C ; Thivat, E ; Mouret-Reynier, M.A ; Kwiatkowski, F ; Pomel, C ; Wang-Lopez, Q ; Chollet, P ; Nabholtz, J.M ; Durando, X</creator><creatorcontrib>Planchat, E ; Abrial, C ; Thivat, E ; Mouret-Reynier, M.A ; Kwiatkowski, F ; Pomel, C ; Wang-Lopez, Q ; Chollet, P ; Nabholtz, J.M ; Durando, X</creatorcontrib><description>Abstract Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the “taxane/anti-aromatase era” for each line given. 529 received CT and 383 hormonotherapy. OS was assessed; from the date of first metastasis and from Day 1 of each CT line. Median OS was 34.1 months; 226 patients received >3 lines of CT with a steady median OS for late lines, 11.4 months per line (range 10.4–12.6). Clinical benefit after the third line of CT was obtained for 29.2–36.6% of patients. CT lasted 11.7 months “on” versus 20.6 months “off” CT. These results may support the use of more than 3 CT lines; each line can contribute to a longer survival.</description><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2011.07.010</identifier><identifier>PMID: 21852136</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Chemotherapy ; Combined Modality Therapy ; Decision Making ; Female ; France ; Hematology, Oncology and Palliative Medicine ; Humans ; Mastectomy ; Medical Oncology ; Metastatic breast Cancer ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Overall survival ; Practice Patterns, Physicians ; Retrospective Studies ; Survival Analysis ; Tumor Response</subject><ispartof>Breast (Edinburgh), 2011-12, Vol.20 (6), p.574-578</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-4c1b286ba6eb38a31017a22f4935d871e0a2fbbb1b56dde483cc4456f4a050633</citedby><cites>FETCH-LOGICAL-c462t-4c1b286ba6eb38a31017a22f4935d871e0a2fbbb1b56dde483cc4456f4a050633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0960977611001603$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21852136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Planchat, E</creatorcontrib><creatorcontrib>Abrial, C</creatorcontrib><creatorcontrib>Thivat, E</creatorcontrib><creatorcontrib>Mouret-Reynier, M.A</creatorcontrib><creatorcontrib>Kwiatkowski, F</creatorcontrib><creatorcontrib>Pomel, C</creatorcontrib><creatorcontrib>Wang-Lopez, Q</creatorcontrib><creatorcontrib>Chollet, P</creatorcontrib><creatorcontrib>Nabholtz, J.M</creatorcontrib><creatorcontrib>Durando, X</creatorcontrib><title>Late lines of treatment benefit survival in metastatic breast cancer in current practice?</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>Abstract Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the “taxane/anti-aromatase era” for each line given. 529 received CT and 383 hormonotherapy. OS was assessed; from the date of first metastasis and from Day 1 of each CT line. Median OS was 34.1 months; 226 patients received >3 lines of CT with a steady median OS for late lines, 11.4 months per line (range 10.4–12.6). Clinical benefit after the third line of CT was obtained for 29.2–36.6% of patients. CT lasted 11.7 months “on” versus 20.6 months “off” CT. These results may support the use of more than 3 CT lines; each line can contribute to a longer survival.</description><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Decision Making</subject><subject>Female</subject><subject>France</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Mastectomy</subject><subject>Medical Oncology</subject><subject>Metastatic breast Cancer</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Overall survival</subject><subject>Practice Patterns, Physicians</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumor Response</subject><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkT1v1TAUhi1URG8L_wAhb0wJx3ZiJ0urqgKKdCUG6NDJsp0TyZd8XGznSv33dZTSgaWTB78fOs9LyEcGJQMmvxxKG9DEVHJgrARVAoM3ZMdqwQsBDZyRHbQSilYpeU4uYjwAQCtk846cc9bUnAm5Iw97k5AOfsJI556mHJlGnBK1OGHvE41LOPmTGaif6IgpF5rkHd26qTOTw7D-uSWE1XcMxmUBXr8nb3szRPzw_F6S-29ff9_eFfuf33_c3uwLV0meisoxyxtpjUQrGiPybcpw3letqLtGMQTDe2sts7XsOqwa4VxV1bKvDNQghbgkn7fcY5j_LhiTHn10OAxmwnmJuoW6lUIplZXVpnRhjjFgr4_BjyY8agZ6ZaoPertLr0w1KJ2ZZtun54LFjti9mP5BzIKrTYD5zJPHoKPzmMF0PqBLupv9aw3_B7i8iHdm-IOPGA_zEqaMUDMduQb9a911nZUxyJkgxBN5yZ8Q</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Planchat, E</creator><creator>Abrial, C</creator><creator>Thivat, E</creator><creator>Mouret-Reynier, M.A</creator><creator>Kwiatkowski, F</creator><creator>Pomel, C</creator><creator>Wang-Lopez, Q</creator><creator>Chollet, P</creator><creator>Nabholtz, J.M</creator><creator>Durando, X</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Late lines of treatment benefit survival in metastatic breast cancer in current practice?</title><author>Planchat, E ; Abrial, C ; Thivat, E ; Mouret-Reynier, M.A ; Kwiatkowski, F ; Pomel, C ; Wang-Lopez, Q ; Chollet, P ; Nabholtz, J.M ; Durando, X</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-4c1b286ba6eb38a31017a22f4935d871e0a2fbbb1b56dde483cc4456f4a050633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Decision Making</topic><topic>Female</topic><topic>France</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Mastectomy</topic><topic>Medical Oncology</topic><topic>Metastatic breast Cancer</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Overall survival</topic><topic>Practice Patterns, Physicians</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumor Response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Planchat, E</creatorcontrib><creatorcontrib>Abrial, C</creatorcontrib><creatorcontrib>Thivat, E</creatorcontrib><creatorcontrib>Mouret-Reynier, M.A</creatorcontrib><creatorcontrib>Kwiatkowski, F</creatorcontrib><creatorcontrib>Pomel, C</creatorcontrib><creatorcontrib>Wang-Lopez, Q</creatorcontrib><creatorcontrib>Chollet, P</creatorcontrib><creatorcontrib>Nabholtz, J.M</creatorcontrib><creatorcontrib>Durando, X</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Planchat, E</au><au>Abrial, C</au><au>Thivat, E</au><au>Mouret-Reynier, M.A</au><au>Kwiatkowski, F</au><au>Pomel, C</au><au>Wang-Lopez, Q</au><au>Chollet, P</au><au>Nabholtz, J.M</au><au>Durando, X</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Late lines of treatment benefit survival in metastatic breast cancer in current practice?</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>20</volume><issue>6</issue><spage>574</spage><epage>578</epage><pages>574-578</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><abstract>Abstract Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the “taxane/anti-aromatase era” for each line given. 529 received CT and 383 hormonotherapy. OS was assessed; from the date of first metastasis and from Day 1 of each CT line. Median OS was 34.1 months; 226 patients received >3 lines of CT with a steady median OS for late lines, 11.4 months per line (range 10.4–12.6). Clinical benefit after the third line of CT was obtained for 29.2–36.6% of patients. CT lasted 11.7 months “on” versus 20.6 months “off” CT. These results may support the use of more than 3 CT lines; each line can contribute to a longer survival.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>21852136</pmid><doi>10.1016/j.breast.2011.07.010</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-9776 |
| ispartof | Breast (Edinburgh), 2011-12, Vol.20 (6), p.574-578 |
| issn | 0960-9776 1532-3080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905963777 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Chemotherapy Combined Modality Therapy Decision Making Female France Hematology, Oncology and Palliative Medicine Humans Mastectomy Medical Oncology Metastatic breast Cancer Neoplasm Metastasis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Overall survival Practice Patterns, Physicians Retrospective Studies Survival Analysis Tumor Response |
| title | Late lines of treatment benefit survival in metastatic breast cancer in current practice? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A22%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Late%20lines%20of%20treatment%20benefit%20survival%20in%20metastatic%20breast%20cancer%20in%20current%20practice?&rft.jtitle=Breast%20(Edinburgh)&rft.au=Planchat,%20E&rft.date=2011-12-01&rft.volume=20&rft.issue=6&rft.spage=574&rft.epage=578&rft.pages=574-578&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2011.07.010&rft_dat=%3Cproquest_cross%3E905963777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905963777&rft_id=info:pmid/21852136&rft_els_id=1_s2_0_S0960977611001603&rfr_iscdi=true |